Agni Bio Selected to Present at AACR Oncology Industry Partnering Event 2026

South San Francisco, CA — March 24, 2026 — Agni Bio, Inc., a biotechnology company advancing next-generation immunotherapies for cancer, today announced that it has been selected for an oral presentation at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients, taking place April 16–17, 2026 at the San Diego Convention Center in San Diego.

Organized by the American Association for Cancer Research, the Oncology Industry Partnering Event brings together leading biotechnology and pharmaceutical companies, investors, and academic innovators to accelerate the translation of scientific discoveries into new cancer therapies. The 2026 event is expected to expand significantly, providing increased opportunities for selected companies to showcase innovative oncology pipelines and technologies.

Agni Bio was selected through a competitive process to participate in a limited number of company presentations highlighting cutting-edge approaches to cancer treatment. The company will present its proprietary platform and pipeline of antigen-dependent bispecific antibodies, including AGB101 (Vβ17 x DLL3) and AGB103 (Vβ17 x CD19).

“We are honored to be selected to present at this highly competitive and impactful event,” said Matt Lorenzi PhD, Chief Scientific Officer and Board member of Agni Bio. “The AACR Oncology Industry Partnering Event provides a unique forum to engage with leaders across academia, industry, and the investment community, and to showcase our approach to expanding the reach of T cell engagers for the treatment of disease.”

The AACR Oncology Industry Partnering Event is held immediately prior to the AACR Annual Meeting 2026, one of the world’s premier cancer research conferences, further enabling collaboration across the global oncology ecosystem.

About Agni Bio
Agni Bio is a biotechnology company based in South San Francisco, CA, focused on developing innovative therapies to address unmet needs in oncology and autoimmune diseases. The company leverages its proprietary bispecific antibody platforms to advance the next frontier in immune cell redirection therapy.

Contact:
Agni Bio, Inc.
communications@agnibiotx.com